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821-3 Evaluation of Beta-Blocker Dose in Community-Based 
Treatment of Heart Failure
Michael B. Fowler, Sandra R. Lottes, Jeanenne J. Nelson, Mary Ann Lukas, Edward M. 
Gilbert, Barry Greenberg, Barry M. Massie, William T. Abraham, Joseph A. Franciosa, 
and the COHERE Participant Physicians, GlaxoSmithKline Pharmaceuticals, 
Philadelphia, PA
Background: Randomized clinical trials (RCT) are performed in a very different environ-
ment from community practice. Heart failure patients in the community tend to be older,
have more comorbidities and are not cared for by the teams of heart failure specialists
who recruit patients into RCT, which may be especially important when beta-adrenergic
blocking drugs are prescribed to patients with heart failure.
Methods: In order to explore these prescribing effects we determined the dose of
carvedilol at end-titration in 4,113 patients in the practice setting and related this to physi-
cian type (cardiologists vs. non-cardiologists), heart failure severity, and the risks of hos-
pitalization and death.
Results: Dose achieved was not related to patients’ age, sex, race, history of diabetes or
other major demographic/clinical factors. The table shows factors that are influenced by
dose. 
Conclusions: Carvedilol dose in the community appears lower than in RCT, is influenced 
by NYHA functional class and tends to be higher when prescribed by cardiologists. At all 
doses, patients taking carvedilol have a lower incidence of death and heart failure hospi-
talization than those not receiving drug. This study demonstrates the utility of beta-
blocker therapy in the community and also confirms the RCT findings that lower doses of 
carvedilol can also provide clinical benefit in the usual care setting.
2:45 p.m.
821-4 Beta-Blockers Reduce Heart Failure Mortality 
Regardless of the Initial Heart Rate: Data From the 
ICONS Study
Jonathan G. Howlett, David E. Johnstone, Jafna L. Cox, Queen Elizabeth II Health 
Sciences Centre, Halifax, NS, Canada
Background: The role of heart rate reduction as a mechanism of beta blockade (BB)
effect in reduction of heart failure (HF) mortality is unknown. We sought to determine
whether the mortality effect of BB was related to initial heart rate in hospitalized HF
patients.
Methods: We utilized a prospective registry-based disease management database, the
Improving Cardiovascular Outcomes in Nova Scotia (ICONS) study, to identify individuals
with a discharge diagnosis of HF from any Nova Scotia hospital between October 15,
1997 and July 1, 2000. Patients were stratified according to their admission heart rate
quintiles in beats/min, (> 115, 100-115, 86-99, 72-85,<72). Variables were recorded pro-
spectively and censored at 2 years.
Results: There were 4888 unique patients, with average age of 76 years; 52% were
female. Patients prescribed BB were younger (age 74 vs. 77), with lower creatinine (133
vs. 143 umol/L) and higher EF (43% vs. 38%). After adjustment for co-morbid conditions,
hazard ratios for mortality with BB at two years were determined: 
Beta blocker prescription at discharge was associated with 37% lower two year mortality
(31% vs. 42%). This finding was consistent regardless of heart rate quintile. The hazard
ratio for BB in those with heart rate <65 bpm was 0.71, p= 0.09.
Conclusion: Beta blockers reduce mortality in unselected patients discharged from hos-
pital with HF regardless of their admission heart rate. Further data is required in those
with severe bradycardia.
3:00 p.m.
821-5 Risks of Death and Hospitalization in Heart Failure 
Patients Receiving Carvedilol Versus Metoprolol 
Tartrate: A Retrospective Claims-Based Study
Thomas E. Delea, Richard H. Stanford, May Hagiwara, John S. Edelsberg, Gerry Oster, 
Policy Analysis Inc., Brookline, MA, GlaxoSmithKline, Research Triangle Park, NC
Background: The Carvedilol or Metoprolol European Trial (COMET) demonstrated
improved survival with carvedilol (C) versus metoprolol tartrate (MT) in patients with
heart failure. The benefits of C versus MT in heart failure patients in typical US clinical
practice are unknown.
Methods: Using a large US health-insurance claims database linked to mortality informa-
tion from the US Social Security Administration, we compared the risks of death and hos-
pitalization and the costs of inpatient care in heart failure patients receiving C versus MT.
Subjects included all persons with >1 prescription for either C or MT (but not both) from
9/97-8/00 who, within 12 months of their first prescription for C or MT, had: (1) >1 medical
encounter with a primary diagnosis of heart failure; (2) >1 prescription for a loop diuretic;
(3) >1 prescription for an angiotensin-converting enzyme inhibitor; (4) no prescriptions for
a beta-blocker; and (5) continuous eligibility for health benefits.
Results: A total of 887 C patients and (coincidentally) an equal number of MT patients
met all criteria for inclusion in the study. Mean follow-up was 11 months (maximum, 36
months). Mean dose prescribed (mg/day supplied) was 24 for C and 70 for MT; mean
dose received (mg/day of follow-up) was only 14 for C and 44 for MT. C patients were
younger, more likely to be men, seen by a cardiologist, and prescribed digoxin; they also
had higher pretreatment heart failure costs. However, they were less likely to have hyper-
tension or other cardiovascular disease, and also had lower pretreatment cardiovascular
costs. Controlling for these differences using Cox proportional hazards regression,
receipt of C versus MT was associated with reduced risk of all-cause mortality (hazard
ratio .78; 95% CI .61-.99) and all-cause hospitalization (hazard ratio .76; 95% CI .66-.89).
In a propensity-matched sample of C and MT patients (n=562 each), expected costs of
cardiovascular inpatient care at 36 months were $6,164 lower for C than MT (95% CI
$1,330-$10,714).
Conclusion: Consistent with findings from COMET, our results suggest that C improves
survival and reduces costs of care compared with MT in heart failure patients in typical
US clinical practice.
3:15 p.m.
821-6 Beta-Blocker Utilization in Patients With Heart Failure: A 
Single-Center, Two-Year Follow-Up
Anoop Parameswaran, W. H. Wilson Tang, Gary S. Francis, Ritesh Gupta, James B. 
Young, Cleveland Clinic Foundation, Cleveland, OH
Background: The longitudinal pattern of beta-blocker (BB) utilization in a heart failure
(HF) practice setting has not been explored. Studies have not addressed the use of BB
over time to determine the “target” rates of use and reasons for discontinuation.
Methods: We reviewed consecutive patients with a clinical diagnosis of HF seen in a
specialized HF clinic between 3/01-5/01, and determined the pattern of BB utilization and
clinical outcomes over a subsequent 2-year period.
Results: From a cohort of 496 patients (mean age 61±14 years, 60% male, 53% with
ischemic etiology, mean LVEF 28±15%), 75% had a trial with a BB. On follow-up at 6, 12,
and 24 months, BB utilization rates were maintained at 69%, 70% and 67%, respectively.
Of the 120 non-BB users, 28 (23%) were subsequently initiated on BB, despite known
relative contraindications in 53% of patients. In 2 years, the discontinuation rate was
10%, and the most common reason for discontinuation was failure to restart BB following
hospitalization (31%). In this non-randomized cohort, the 2-year all-cause mortality was
comparable among different BBs (Figure).
Conclusion: Utilization rates of BB in our HF clinic remain constant (67-70%) throughout
a 2-year follow-up and likely represents a reasonable “target”. Of those who discontinued
Patient Characteristics 
and Outcomes
Carvedilol dose at end-titration (mg bid)
0 mg 3.125 mg 6.25 mg 12.5 mg 25 mg 50 mg
No. Patients 386 416 722 759 1672 158
Dose distribution in NYHA 
I patients (n=445)
7% 7% 17% 17% 46% 5%
Dose distribution in NYHA 
II patients (n=2099)
9% 9% 16% 18% 43% 4%
Dose distribution in NYHA 
III patients (n=1390)
11% 11% 18% 19% 38% 3%
Dose distribution in NYHA 
IV patients (n=131)
5% 18% 30% 21% 23% 4%
Dose distribution in 
cardiologists’ patients 
(n=2994)
10% 8% 14% 17% 47% 4%
Dose distribution in non-
cardiologists’ patients 
(n=1119)
7% 17% 27% 21% 24% 4%
HF hospitalizations per 
dose group
22% 17% 14% 11% 9% 8%
Odds ratio of HF 
hospitalizations (95% CI)
ref 0.71
(0.48-
1.06)p=0.097
4
0.59
(0.42-
0.85)p=0.0043
0.47
(0.33-
0.68)p<0.0001
0.44
(0.32-
0.62)p<0.0001
0.42
(0.21-
0.84)p=0.0137
KM rate per dose group 17% 11% 10% 7% 5% 5%
Hazard ratio for death 
(95% CI)
ref 0.66
(0.42-
1.05)p=0.078
0
0.55
(0.36-
0.84)p=0.0060
0.35
(0.22-
0.54)p<0.0001
0.25
(0.18-
0.39)p<0.0001
0.38
(0.16-0.93)p=0.034
ref = referent group for Odds Ratio and Hazard Ratio is the 0 mg dose group
KM rate = Kaplan-Meier rate for all-cause mortality
Initial Heart Rate (beats/min) Hazard Ratio 95% CI p Value
> 115 (n=990) 0.54 0.42- 0.71 0.0001
100-115 (n=1006) 0.62 0.47- 0.80 0.0003
86-99 (n=977) 0.57 0.44 - 0.75 0.0001
72-85 (n=1015) 0.61 0.47-0.79 0.0002
< 72 (n=900) 0.69 0.52- 0.92 0.002
